Drug makers Merck and Schering-Plough never published the results of studies regarding Zetia, an anti-hyperlipidemic drug often prescribed to lower cholesterol levels. The studies raise issues about Zetias effect on the liver. Enhance, one research study of Zetia, was completed in April of 2006.
The results of Enhance have recently been discovered. The study contains information about Zetias risks on the liver. Some patients showed elevated liver enzymes and were dropped from the study. Merck and Schering-Plough who have been criticized for not releasing the results of the Enhance study, are said to probably earn around $5 billion from Zetia … Read the rest